# REC-7735

Source: https://onco.cc/drugs/rec-7735/  
OnCo record `rec-7735` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

REC-7735 is an experimental small molecule, mutant-selective PI3K-alpha inhibitor from Recursion Pharmaceuticals, in phase 1 trials for HR-positive / HER2-negative breast cancer with PIK3CA H1047R and solid tumours.

## Summary

REC-7735 is a small molecule, mutant-selective PI3K-alpha inhibitor from Recursion Pharmaceuticals. A PI3K-alpha H1047R mutant-selective inhibitor, designed to avoid the dose-limiting high blood sugar seen with inhibitors of normal (wild-type) PI3K-alpha. Its furthest stage is phase 1, for HR-positive / HER2-negative breast cancer with PIK3CA H1047R and solid tumours. ClinicalTrials.gov registers it in one study linked below. Pipeline page: 'Status: Phase 1'. Registry NCT07819136 (phase 1/2) recruiting. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: REC-7735
- Modality: Small molecule, mutant-selective PI3K-alpha inhibitor
- Mechanism: A PI3K-alpha H1047R mutant-selective inhibitor, designed to avoid the dose-limiting high blood sugar seen with inhibitors of normal (wild-type) PI3K-alpha.

## Sources

- Recursion Pharmaceuticals: recursion.com: https://www.recursion.com/pipeline
- Recursion Pharmaceuticals: recursion.com: https://www.recursion.com/pipeline
- ClinicalTrials.gov: trials of REC-7735: https://clinicaltrials.gov/search?intr=REC-7735

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- targets: [PIK3CA / PI3K-alpha](https://onco.cc/targets/pik3ca/)
- companies: [Recursion Pharmaceuticals](https://onco.cc/companies/recursion/)
- trials: [REC-7735 in Participants With Solid Tumors](https://onco.cc/trials/nct07819136/)

---
JSON: https://onco.cc/api/v1/entities/rec-7735.json